iFCI001
CRICKi001-A
General
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 5-9 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
KaryoStat™ analysis of the iPSC line revealed the sample originated from a male individual No chromosomal aberrations were found when comparing against the reference dataset (Figure 6)
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA13299075 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | LONDON - CAMDEN & KINGS CROSS RESEARCH ETHICS COMMITTEE |
| Approval number | 17/LO/0981 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
A tube-like invagination of the epidermis from which the hair shaft develops and into which the sebaceous glands open; the follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis.
Synonyms
|
| Age of donor (at collection) | 5-9 |
| Collected in | 2019 |
| Passage number reprogrammed | 2 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| NANOG |
Yes |
|
| Pluripotency Score | Novelty Score | |
| 41.78 | 1.23 |
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
MALE NO CHROMOSOMAL ABERRATIONS
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.